免疫检查点阻断的癌症治疗：最新进展与展望

叶弘颖; 廖炜杰; 潘炯利; 诗音; 王青青

doi:10.1631/jzus.B2300492

Your Location：

Home >

Browse articles >

免疫检查点阻断的癌症治疗：最新进展与展望

Scan QR Code

文章被引用时，请邮件提醒。

Submit

Review | Updated：2025-03-13

免疫检查点阻断的癌症治疗：最新进展与展望
Immune checkpoint blockade for cancer therapy: current progress and perspectives
浙江大学学报（英文版）（B辑：生物医学和生物技术） 2025年26卷第3期页码：203-226
Affiliations：

1.Institute of Immunology, Zhejiang University School of Medicine, Hangzhou 310058, China
2.The Key Laboratory for Immunity and Inflammatory Diseases of Zhejiang Province, Hangzhou 310058, China
3.Department of Biochemistry, Zhejiang University School of Medicine, Hangzhou 310058, China
Funds：

the National Key Research and Development Program of China(2022YFE0102100);the National Natural Science Foundation of China(U22A20307;81930041)
DOI：10.1631/jzus.B2300492
中图分类号：
CSTR：
收稿日期：2023-07-11，

修回日期：2023-12-05，

纸质出版日期：2025-03-13
Accepted：

叶弘颖,廖炜杰,潘炯利等.免疫检查点阻断的癌症治疗：最新进展与展望[J].浙江大学学报（英文版）（B辑：生物医学和生物技术）,2025,26(03):203-226.

Hongying YE, Weijie LIAO, Jiongli PAN, et al. Immune checkpoint blockade for cancer therapy: current progress and perspectives[J]. Journal of zhejiang university-science b (biomedicine & biotechnology), 2025, 26(3): 203-226.
叶弘颖,廖炜杰,潘炯利等.免疫检查点阻断的癌症治疗：最新进展与展望[J].浙江大学学报（英文版）（B辑：生物医学和生物技术）,2025,26(03):203-226. DOI： 10.1631/jzus.B2300492.

Hongying YE, Weijie LIAO, Jiongli PAN, et al. Immune checkpoint blockade for cancer therapy: current progress and perspectives[J]. Journal of zhejiang university-science b (biomedicine & biotechnology), 2025, 26(3): 203-226. DOI： 10.1631/jzus.B2300492.

摘要

抗肿瘤免疫反应的功能缺陷对癌症进展至关重要。免疫检查点阻断（ICB）可增强T细胞反应，是宿主抗肿瘤免疫正常化的有效策略。近年来，多项表达于肿瘤细胞和免疫细胞的免疫检查点已被鉴定，其中一些显示出良好的成药性，并已获得美国食品药品监督管理局（FDA）的批准用于临床治疗。然而，有限的治疗反应和免疫相关不良事件（irAEs）不容忽视。本文综述了ICB的发展和应用，并就基于ICB的癌症免疫疗法克服耐药性的潜在策略和未来方向展开讨论。

Abstract

Dysfunction of anti-tumor immune responses is crucial for cancer progression. Immune checkpoint blockade (ICB)

which can potentiate T cell responses

is an effective strategy for the normalization of host anti-tumor immunity. In recent years

immune checkpoints

expressed on both tumor cells and immune cells

have been identified; some of them have exhibited potential druggability and have been approved by the US Food and Drug Administration (FDA) for clinical treatment. However

limited responses and immune-related adverse events (irAEs) cannot be ignored. This review outlines the development and applications of ICBs

potential strategies for overcoming resistance

and future directions for ICB-based cancer immunotherapy.

关键词

Keywords

references

Abu-Sbeih H , Ali FS , Qiao W , et al. , 2019 . Immune checkpoint inhibitor-induced colitis as a predictor of survival in metastatic melanoma . Cancer Immunol Immunother , 68 ( 4 ): 553 - 561 . https://doi.org/10.1007/s00262-019-02303-1 https://doi.org/10.1007/s00262-019-02303-1

Advani R , Flinn I , Popplewell L , et al. , 2018 . CD47 blockade by Hu5F9-G4 and rituximab in non-Hodgkin’s lymphoma . N Engl J Med , 379 ( 18 ): 1711 - 1721 . https://doi.org/10.1056/NEJMoa1807315 https://doi.org/10.1056/NEJMoa1807315

Aggarwal C , Prawira A , Antonia S , et al. , 2022 . Dual checkpoint targeting of B7-H3 and PD-1 with enoblituzumab and pembrolizumab in advanced solid tumors: interim results from a multicenter phase I/II trial . J Immunother Cancer , 10 ( 4 ): e004424 . https://doi.org/10.1136/jitc-2021-004424 https://doi.org/10.1136/jitc-2021-004424

Ahn M , 2018 . MS28.02 Combination IO+IO . J Thorac Oncol , 13 ( 10 S): S299 - S300 . https://doi.org/10.1016/j.jtho.2018.08.194 https://doi.org/10.1016/j.jtho.2018.08.194

Almutairi AR , McBride A , Slack M , et al. , 2020 . Potential immune-related adverse events associated with monotherapy and combination therapy of ipilimumab, nivolumab, and pembrolizumab for advanced melanoma: a systematic review and meta-analysis . Front Oncol , 10 : 91 . https://doi.org/10.3389/fonc.2020.00091 https://doi.org/10.3389/fonc.2020.00091

Andrews LP , Marciscano AE , Drake CG , et al. , 2017 . LAG3 (CD223) as a cancer immunotherapy target . Immunol Rev , 276 ( 1 ): 80 - 96 . https://doi.org/10.1111/imr.12519 https://doi.org/10.1111/imr.12519

Andrews LP , Yano H , Vignali DAA , 2019 . Inhibitory receptors and ligands beyond PD-1, PD-L1 and CTLA-4: breakthroughs or backups . Nat Immunol , 20 ( 11 ): 1425 - 1434 . https://doi.org/10.1038/s41590-019-0512-0 https://doi.org/10.1038/s41590-019-0512-0

Arredouani MS , Franco F , Imrich A , et al. , 2007 . Scavenger receptors SR-AI/II and MARCO limit pulmonary dendritic cell migration and allergic airway inflammation . J Immunol , 178 ( 9 ): 5912 - 5920 . https://doi.org/10.4049/jimmunol.178.9.5912 https://doi.org/10.4049/jimmunol.178.9.5912

Asrir A , Tardiveau C , Coudert J , et al. , 2022 . Tumor-associated high endothelial venules mediate lymphocyte entry into tumors and predict response to PD-1 plus CTLA-4 combin ation immunotherapy. Cancer Cell , 40 ( 30 ): 318 - 334.e9 . https://doi.org/10.1016/j.ccell.2022.01.002 https://doi.org/10.1016/j.ccell.2022.01.002

Attia P , Phan GQ , Maker AV , et al. , 2005 . Autoimmunity correlates with tumor regression in patients with metastatic melanoma treated with anti-cytotoxic T-lymphocyte antigen-4 . J Clin Oncol , 23 ( 25 ): 6043 - 6053 . https://doi.org/10.1200/jco.2005.06.205 https://doi.org/10.1200/jco.2005.06.205

Attrill GH , Owen CN , Ahmed T , et al. , 2022 . Higher proportions of CD39+ tumor-resident cytotoxic T cells predict recurrence-free survival in patients with stage III melanoma treated with adjuvant immunotherapy . J Immunother Cancer , 10 ( 6 ): e004771 . https://doi.org/10.1136/jitc-2022-004771 https://doi.org/10.1136/jitc-2022-004771

Bally APR , Lu PY , Tang Y , et al. , 2015 . NF-κB regulates PD-1 expression in macrophages . J Immunol , 194 ( 9 ): 4545 - 4554 . https://doi.org/10.4049/jimmunol.1402550 https://doi.org/10.4049/jimmunol.1402550

Barkal AA , Weiskopf K , Kao KS , et al. , 2018 . Engagement of MHC class I by the inhibitory receptor LILRB1 suppresses macrophages and is a target of cancer immunotherapy . Nat Immunol , 19 ( 1 ): 76 - 84 . https://doi.org/10.1038/s41590-017-0004-z https://doi.org/10.1038/s41590-017-0004-z

Barrueto L , Caminero F , Cash L , et al. , 2020 . Resistance to checkpoint inhibition in cancer immunotherapy . Transl Oncol , 13 ( 3 ): 100738 . https://doi.org/10.1016/j.tranon.2019.12.010 https://doi.org/10.1016/j.tranon.2019.12.010

Benci JL , Xu BH , Qiu Y , et al. , 2016 . Tumor interferon signaling regulates a multigenic resistance program to immune checkpoint blockade . Cell , 167 ( 6 ): 1540 - 1554.e12 . https://doi.org/10.1016/j.cell.2016.11.022 https://doi.org/10.1016/j.cell.2016.11.022

Borcoman E , Kanjanapan Y , Champiat S , et al. , 2019 . Novel patterns of response under immunotherapy . Ann Oncol , 30 ( 3 ): 385 - 396 . https://doi.org/10.1093/annonc/mdz003 https://doi.org/10.1093/annonc/mdz003

Brahmer JR , Lacchetti C , Schneider BJ , et al. , 2018 . Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American Society of Clinical Oncology Clinical Practice Guideline . J Clin Oncol , 36 ( 17 ): 1714 - 1768 . https://doi.org/10.1200/jco.2017.77.6385 https://doi.org/10.1200/jco.2017.77.6385

Briukhovetska D , Dörr J , Endres S , et al. , 2021 . Interleukins in cancer: from biology to therapy . Nat Rev Cancer , 21 ( 8 ): 481 - 499 . https://doi.org/10.1038/s41568-021-00363-z https://doi.org/10.1038/s41568-021-00363-z

Burshtyn DN , Morcos C , 2016 . The expanding spectrum of ligands for leukocyte Ig-like receptors . J Immunol , 196 ( 3 ): 947 - 955 . https://doi.org/10.4049/jimmunol.1501937 https://doi.org/10.4049/jimmunol.1501937

Casado JG , Pawelec G , Morgado S , et al. , 2009 . Expression of adhesion molecules and ligands for activating and costimulatory receptors involved in cell-mediated cytotoxicity in a large panel of human melanoma cell lines . Cancer Immunol Immunother , 58 ( 9 ): 1517 - 1526 . https://doi.org/10.1007/s00262-009-0682-y https://doi.org/10.1007/s00262-009-0682-y

Castro F , Cardoso AP , Gonçalves RM , et al. , 2018 . Interferon-gamma at the crossroads of tumor immune surveillance or evasion . Front Immunol , 9 : 847 . https://doi.org/10.3389/fimmu.2018.00847 https://doi.org/10.3389/fimmu.2018.00847

Ceeraz S , Nowak EC , Noelle RJ , 2013 . B7 family checkpoint regulators in immune regulation and disease . Trends Immunol , 34 ( 11 ): 556 - 563 . https://doi.org/10.1016/j.it.2013.07.003 https://doi.org/10.1016/j.it.2013.07.003

Champiat S , Dercle L , Ammari S , et al. , 2017 . Hyperprogressive disease is a new pattern of progression in cancer patients treated by anti-PD-1/PD-L1 . Clin Cancer Res , 23 ( 8 ): 1920 - 1928 . https://doi.org/10.1158/1078-0432.Ccr-16-1741 https://doi.org/10.1158/1078-0432.Ccr-16-1741

Chapoval AI , Ni J , Lau JS , et al. , 2001 . B7-H3: a costimulatory molecule for T cell activation and IFN-γ production . Nat Immunol , 2 ( 3 ): 269 - 274 . https://doi.org/10.1038/85339 https://doi.org/10.1038/85339

Chen DS , Mellman I , 2017 . Elements of cancer immunity and the cancer‒immune set point . Nature , 541 ( 7637 ): 321 - 330 . https://doi.org/10.1038/nature21349 https://doi.org/10.1038/nature21349

Chen GY , Tang J , Zheng P , et al. , 2009 . CD24 and Siglec-10 selectively repress tissue damage‒induced immune responses . Science , 323 ( 5922 ): 1722 - 1725 . https://doi.org/10.1126/science.1168988 https://doi.org/10.1126/science.1168988

Chen GY , Chen X , King S , et al. , 2011 . Amelioration of sepsis by inhibiting sialidase-mediated disruption of the CD24-siglecg interaction . Nat Biotechnol , 29 ( 5 ): 428 - 435 . https://doi.org/10.1038/nbt.1846 https://doi.org/10.1038/nbt.1846

Chen LP , Flies DB , 2013 . Molecular mechanisms of T cell co-stimulation and co-inhibition . Nat Rev Immunol , 13 ( 4 ): 227 - 242 . https://doi.org/10.1038/nri3405 https://doi.org/10.1038/nri3405

Cheung TC , Oborne LM , Steinberg MW , et al. , 2009 . T cell intrinsic heterodimeric complexes between HVEM and BTLA determine receptivity to the surrounding microenvironment . J Immunol , 183 ( 11 ): 7286 - 7296 . https://doi.org/10.4049/jimmunol.0902490 https://doi.org/10.4049/jimmunol.0902490

Chiba S , Baghdadi M , Akiba H , et al. , 2012 . Tumor-infiltrating DCs suppress nucleic acid-mediated innate immune responses through interactions between the receptor TIM-3 and the alarmin HMGB1 . Nat Immunol , 13 ( 9 ): 832 - 842 . https://doi.org/10.1038/ni.2376 https://doi.org/10.1038/ni.2376

Choi IH , Zhu GF , Sica GL , et al. , 2003 . Genomic organization and expression analysis of B7-H4, an immune inhibitory molecule of the B7 family . J Immunol , 171 ( 9 ): 4650 - 4654 . https://doi.org/10.4049/jimmunol.171.9.4650 https://doi.org/10.4049/jimmunol.171.9.4650

Chowell D , Morris LGT , Grigg CM , et al. , 2018 . Patient HLA class I genotype influences cancer response to checkpoint blockade immunotherapy . Science , 359 ( 6375 ): 582 - 587 . https://doi.org/10.1126/science.aao4572 https://doi.org/10.1126/science.aao4572

Das M , Zhu C , Kuchroo VK , 2017 . TIM-3 and its role in regulating anti-tumor immunity . Immunol Rev , 276 ( 1 ): 97 - 111 . https://doi.org/10.1111/imr.12520 https://doi.org/10.1111/imr.12520

Davar D , Boasberg PD , Eroglu Z , et al. , 2018 . A phase 1 study of TSR-022, an anti-TIM-3 monoclonal antibody, in combination with TSR-042 (anti-PD-1) in patients with colorectal cancer and post-PD-1 NSCLC and melanoma . J Immunother Therapy Cancer , 6 ( S1 ): S115 .

Dixon KO , Tabaka M , Schramm MA , et al. , 2021 . TIM-3 restrains anti-tumour immunity by regulating inflammasome activation . Nature , 595 ( 7865 ): 101 - 106 . https://doi.org/10.1038/s41586-021-03626-9 https://doi.org/10.1038/s41586-021-03626-9

Dolladille C , Ederhy S , Sassier M , et al. , 2020 . Immune checkpoint inhibitor rechallenge after immune-related adverse events in patients with cancer . JAMA Oncol , 6 ( 6 ): 865 - 871 . https://doi.org/10.1001/jamaoncol.2020.0726 https://doi.org/10.1001/jamaoncol.2020.0726

Dong HD , Strome SE , Salomao DR , et al. , 2002 . Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion . Nat Med , 8 ( 8 ): 793 - 800 . https://doi.org/10.1038/nm730 https://doi.org/10.1038/nm730

Downey SG , Klapper JA , Smith FO , et al. , 2007 . Prognostic factors related to clinical response in patients with metastatic melanoma treated by CTL-associated antigen-4 blockade . Clin Cancer Res , 13 ( 22 Pt 1 ): 6681 - 6688 . https://doi.org/10.1158/1078-0432.Ccr-07-0187 https://doi.org/10.1158/1078-0432.Ccr-07-0187

Dunn GP , Bruce AT , Ikeda H , et al. , 2002 . Cancer immunoediting: from immunosurveillance to tumor escape . Nat Immunol , 3 ( 11 ): 991 - 998 . https://doi.org/10.1038/ni1102-991 https://doi.org/10.1038/ni1102-991

Eltanbouly MA , Schaafsma E , Noelle RJ , et al. , 2020 . VISTA: coming of age as a multi-lineage immune checkpoint . Clin Exp Immunol , 200 ( 2 ): 120 - 130 . https://doi.org/10.1111/cei.13415 https://doi.org/10.1111/cei.13415

Ficial M , Jegede OA , Sant'Angelo M , et al. , 2021 . Expression of T-cell exhaustion molecules and human endogenous retroviruses as predictive biomarkers for response to nivolumab in metastatic clear cell renal cell carcinoma . Clin Cancer Res , 27 ( 5 ): 1371 - 1380 . https://doi.org/10.1158/1078-0432.CCR-20-3084 https://doi.org/10.1158/1078-0432.CCR-20-3084

Finn RS , Qin SK , Ikeda M , et al. , 2020 . Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma . N Engl J Med , 382 ( 20 ): 1894 - 1905 . https://doi.org/10.1056/NEJMoa1915745 https://doi.org/10.1056/NEJMoa1915745

Flies DB , Han X , Higuchi T , et al. , 2014 . Coinhibitory receptor PD-1H preferentially suppresses CD4 + T cell-mediated immunity . J Clin Invest , 124 ( 5 ): 1966 - 1975 . https://doi.org/10.1172/JCI74589 https://doi.org/10.1172/JCI74589

Fourcade J , Sun ZJ , Benallaoua M , et al. , 2010 . Upregulation of Tim-3 and PD-1 expression is associated with tumor antigen‒specific CD8 + T cell dysfunction in melanoma patients . J Exp Med , 207 ( 10 ): 2175 - 2186 . https://doi.org/10.1084/jem.20100637 https://doi.org/10.1084/jem.20100637

Francisco LM , Sage PT , Sharpe AH , 2010 . The PD-1 pathway in tolerance and autoimmunity . Immunol Rev , 236 ( 1 ): 219 - 242 . https://doi.org/10.1111/j.1600-065X.2010.00923.x https://doi.org/10.1111/j.1600-065X.2010.00923.x

Fresno Vara JÁ , Casado E , de Castro J , et al. , 2004 . PI3K/Akt signalling pathway and cancer . Cancer Treat Rev , 30 ( 2 ): 193 - 204 . https://doi.org/10.1016/j.ctrv.2003.07.007 https://doi.org/10.1016/j.ctrv.2003.07.007

Ganesan S , Mehnert J , 2020 . Biomarkers for response to immune checkpoint blockade . Annu Rev Cancer Biol , 4 ( 1 ): 331 - 351 . https://doi.org/10.1146/annurev-cancerbio-030419-033604 https://doi.org/10.1146/annurev-cancerbio-030419-033604

Gao X , Zhu YB , Li G , et al. , 2012 . TIM-3 expression characterizes regulatory T cells in tumor tissues and is associated with lung cancer progression . PLoS ONE , 7 ( 2 ): e30676 . https://doi.org/10.1371/journal.pone.0030676 https://doi.org/10.1371/journal.pone.0030676

Gavrieli M , Watanabe N , Loftin SK , et al. , 2003 . Characterization of phosphotyrosine binding motifs in the cytoplasmic domain of B and T lymphocyte attenuator required for association with protein tyrosine phosphatases SHP-1 and SHP-2 . Biochem Biophys Res Commun , 312 ( 4 ): 1236 - 1243 . https://doi.org/10.1016/j.bbrc.2003.11.070 https://doi.org/10.1016/j.bbrc.2003.11.070

Geraud A , Gougis P , Vozy A , et al. , 2021 . Clinical pharmacology and interplay of immune checkpoint agents: a Yin-Yang balance . Annu Rev Pharmacol Toxicol , 61 : 85 - 112 . https://doi.org/10.1146/annurev-pharmtox-022820-093805 https://doi.org/10.1146/annurev-pharmtox-022820-093805

Goel S , Decristo MJ , Watt AC , et al. , 2017 . CDK4/6 inhibition triggers anti-tumour immunity . Nature , 548 ( 7668 ): 471 - 475 . https://doi.org/10.1038/nature23465 https://doi.org/10.1038/nature23465

Gomes de Morais AL , Cerdá S , de Miguel M , 2022 . New checkpoint inhibitors on the road: targeting TIM-3 in solid tumors . Curr Oncol Rep , 24 ( 5 ): 651 - 658 . https://doi.org/10.1007/s11912-022-01218-y https://doi.org/10.1007/s11912-022-01218-y

Gonzalez LC , Loyet KM , Calemine-Fenaux J , et al. , 2005 . A coreceptor interaction between the CD28 and TNF receptor family members B and T lymphocyte attenuator and herpesvirus entry mediator . Proc Natl Acad Sci USA , 102 ( 4 ): 1116 - 1121 . https://doi.org/10.1073/pnas.0409071102 https://doi.org/10.1073/pnas.0409071102

Grasso CS , Tsoi J , Onyshchenko M , et al. , 2020 . Conserved interferon-γ signaling drives clinical response to immune checkpoint blockade therapy in melanoma . Cancer Cell , 38 ( 4 ): 500 - 515.e3 . https://doi.org/10.1016/j.ccell.2020.08.005 https://doi.org/10.1016/j.ccell.2020.08.005

Hall ET , Singhal S , Dickerson J , et al. , 2019 . Patient-reported outcomes for cancer patients receiving checkpoint inhibitors: opportunities for palliative care—a systematic review . J Pain Symptom Manage , 58 ( 1 ): 137 - 156.e1 . https://doi.org/10.1016/j.jpainsymman.2019.03.015 https://doi.org/10.1016/j.jpainsymman.2019.03.015

Han P , Goularte OD , Rufner K , et al. , 2004 . An inhibitory Ig superfamily protein expressed by lymphocytes and APCs is also an early marker of thymocyte positive selection . J Immunol , 172 ( 10 ): 5931 - 5939 . https://doi.org/10.4049/jimmunol.172.10.5931 https://doi.org/10.4049/jimmunol.172.10.5931

Hannier S , Tournier M , Bismuth G , et al. , 1998 . CD3/TCR complex-associated lymphocyte activation gene-3 molecules inhibit CD3/TCR signaling . J Immunol , 161 ( 8 ): 4058 - 4065 . https://doi.org/10.4049/jimmunol.161.8.4058 https://doi.org/10.4049/jimmunol.161.8.4058

Harding JJ , Patnaik A , Moreno V , et al. , 2019 . A phase Ia/Ib study of an anti-TIM-3 antibody (LY3321367) monotherapy or in combination with an anti-PD-L1 antibody (LY3300054): interim safety, efficacy, and pharmacokinetic findings in advanced cancers . J Clin Oncol , 37 ( 8 ): 12 - 12 . https://doi.org/10.1200/JCO.2019.37.8_suppl.12 https://doi.org/10.1200/JCO.2019.37.8_suppl.12

Harding JJ , Moreno V , Bang YJ , et al. , 2021 . Blocking TIM-3 in treatment-refractory advanced solid tumors: a phase Ia/b study of LY3321367 with or without an anti-PD-L1 antibody . Clin Cancer Res , 27 ( 8 ): 2168 - 2178 . https://doi.org/10.1158/1078-0432.Ccr-20-4405 https://doi.org/10.1158/1078-0432.Ccr-20-4405

Held W , Mariuzza RA , 2008 . Cis interactions of immunoreceptors with MHC and non-MHC ligands . Nat Rev Immunol , 8 ( 4 ): 269 - 278 . https://doi.org/10.1038/nri2278 https://doi.org/10.1038/nri2278

Higgs BW , Morehouse CA , Streicher K , et al. , 2018 . Interferon gamma messenger RNA signature in tumor biopsies predicts outcomes in patients with non-small cell lung carcin oma or urothelial cancer treated with durvalumab. Clin Cancer Res , 24 ( 16 ): 3857 - 3866 . https://doi.org/10.1158/1078-0432.CCR-17-3451 https://doi.org/10.1158/1078-0432.CCR-17-3451

Hirayama S , Ishii G , Nagai K , et al. , 2012 . Prognostic impact of CD204-positive macrophages in lung squamous cell carcinoma: possible contribution of CD204-positive macrophages to the tumor-promoting microenvironment . J Thorac Oncol , 7 ( 12 ): 1790 - 1797 . https://doi.org/10.1097/JTO.0b013e3182745968 https://doi.org/10.1097/JTO.0b013e3182745968

Hodi FS , O'Day SJ , McDermott DF , et al. , 2010 . Improved survival with ipilimumab in patients with metastatic melanoma . N Engl J Med , 363 ( 8 ): 711 - 723 . https://doi.org/10.1056/NEJMoa1003466 https://doi.org/10.1056/NEJMoa1003466

Hollebecque A , Chung HC , de Miguel MJ , et al. , 2021 . Safety and antitumor activity of α-PD-L1 antibody as monotherapy or in combination with α-TIM-3 antibody in patients with microsatellite instability-high/mismatch repair-deficient tumors . Clin Cancer Res , 27 ( 23 ): 6393 - 6404 . https://doi.org/10.1158/1078-0432.Ccr-21-0261 https://doi.org/10.1158/1078-0432.Ccr-21-0261

Holtzhausen A , Zhao F , Evans KS , et al. , 2015 . Melanoma-derived Wnt5a promotes local dendritic-cell expression of IDO and immunotolerance: opportunities for pharmacologic enhancement of immunotherapy . Cancer Immunol Res , 3 ( 9 ): 1082 - 1095 . https://doi.org/10.1158/2326-6066.Cir-14-0167 https://doi.org/10.1158/2326-6066.Cir-14-0167

Hone Lopez S , Jalving M , Fehrmann RSN , et al. , 2022 . The gut wall’s potential as a partner for precision oncology in immune checkpoint treatment . Cancer Treat Rev , 107 : 102406 . https://doi.org/10.1016/j.ctrv.2022.102406 https://doi.org/10.1016/j.ctrv.2022.102406

Huang CT , Workman CJ , Flies D , et al. , 2004 . Role of LAG-3 in regulatory T cells . Immunity , 21 ( 4 ): 503 - 513 . https://doi.org/10.1016/j.immuni.2004.08.010 https://doi.org/10.1016/j.immuni.2004.08.010

Huang X , Zhang XZ , Li EL , et al. , 2020 . VISTA: an immune regulatory protein checking tumor and immune cells in cancer immunotherapy . J Hematol Oncol , 13 : 83 . https://doi.org/10.1186/s13045-020-00917-y https://doi.org/10.1186/s13045-020-00917-y

Huang YH , Zhu C , Kondo Y , et al. , 2015 . CEACAM1 regulates TIM-3-mediated tolerance and exhaustion . Nature , 517 ( 7534 ): 386 - 390 . https://doi.org/10.1038/nature13848 https://doi.org/10.1038/nature13848

Hurchla MA , Sedy JR , Gavrielli M , et al. , 2005 . B and T lymphocyte attenuator exhibits structural and expression polymorphisms and is highly induced in anergic <math id="M1"><mi mathvariant="normal">C</mi><msubsup><mrow><mi mathvariant="normal">D</mi></mrow><mrow><mn mathvariant="normal">4</mn></mrow><mrow><mo>+</mo></mrow></msubsup></math> https://html.publish.founderss.cn/rc-pub/api/common/picture?pictureId=75418278&type= https://html.publish.founderss.cn/rc-pub/api/common/picture?pictureId=75418264&type= 5.50333309 3.47133350 T cells . J Immunol , 174 ( 6 ): 3377 - 3385 . https://doi.org/10.4049/jimmunol.174.6.3377 https://doi.org/10.4049/jimmunol.174.6.3377

Iivanainen S , Alanko T , Vihinen P , et al. , 2020 . Follow-up of cancer patients receiving anti-PD-(L)1 therapy using an electronic patient-reported outcomes tool (KISS): prospective feasibility cohort study . JMIR Form Res , 4 ( 10 ): e17898 . https://doi.org/10.2196/17898 https://doi.org/10.2196/17898

Ishida Y , Agata Y , Shibahara K , et al. , 1992 . Induced expression of PD-1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death . EMBO J , 11 ( 11 ): 3887 - 3895 . https://doi.org/10.1002/j.1460-2075.1992.tb05481.x https://doi.org/10.1002/j.1460-2075.1992.tb05481.x

Janakiram M , Shah UA , Liu WF , et al. , 2017 . The third group of the B7-CD28 immune checkpoint family: HHLA2, TMIGD 2, B 7 x, and B7 - H3 . Immunol Rev, 276 ( 1 ): 26 - 39 . https://doi.org/10.1111/imr.12521 https://doi.org/10.1111/imr.12521

Johnson DB , Balko JM , Compton ML , et al. , 2016 . Fulminant myocarditis with combination immune checkpoint blockade . N Engl J Med , 375 ( 18 ): 1749 - 1755 . https://doi.org/10.1056/NEJMoa1609214 https://doi.org/10.1056/NEJMoa1609214

Johnston RJ , Su LJ , Pinckney J , et al. , 2019 . VISTA is an acidic pH-selective ligand for PSGL-1 . Nature , 574 ( 7779 ): 565 - 570 . https://doi.org/10.1038/s41586-019-1674-5 https://doi.org/10.1038/s41586-019-1674-5

Joller N , Hafler JP , Brynedal B , et al. , 2011 . Cutting edge: TIGIT has T cell-intrinsic inhibitory functions . J Immunol , 186 ( 3 ): 1338 - 1342 . https://doi.org/10.4049/jimmunol.1003081 https://doi.org/10.4049/jimmunol.1003081

Kalbasi A , Ribas A , 2020 . Tumour-intrinsic resistance to immune checkpoint blockade . Nat Rev Immunol , 20 ( 1 ): 25 - 39 . https://doi.org/10.1038/s41577-019-0218-4 https://doi.org/10.1038/s41577-019-0218-4

Keir ME , Butte MJ , Freeman GJ , et al. , 2008 . PD-1 and its ligands in tolerance and immunity . Annu Rev Immunol , 26 : 677 - 704 . https://doi.org/10.1146/annurev.immunol.26.021607.090331 https://doi.org/10.1146/annurev.immunol.26.021607.090331

Kim TK , Vandsemb EN , Herbst RS , et al. , 2022 . Adaptive immune resistance at the tumour site: mechanisms and therapeutic opportunities . Nat Rev Drug Discov , 21 ( 7 ): 529 - 540 . https://doi.org/10.1038/s41573-022-00493-5 https://doi.org/10.1038/s41573-022-00493-5

Kisielow M , Kisielow J , Capoferri-Sollami G , et al. , 2005 . Expression of lymphocyte activation gene 3 (LAG-3) on B cells is induced by T cells . Eur J Immunol , 35 ( 7 ): 2081 - 2088 . https://doi.org/10.1002/eji.200526090 https://doi.org/10.1002/eji.200526090

Kok IC , Hooiveld JS , van de Donk PP , et al. , 2022 . 89 Zr-pembrolizumab imaging as a non-invasive approach to assess clinical response to PD-1 blockade in cancer . Ann Oncol , 33 ( 1 ): 80 - 88 . https://doi.org/10.1016/j.annonc.2021.10.213 https://doi.org/10.1016/j.annonc.2021.10.213

Kontos F , Michelakos T , Kurokawa T , et al. , 2021 . B7-H3: an attractive target for antibody-based immunotherapy . Clin Cancer Res , 27 ( 5 ): 1227 - 1235 . https://doi.org/10.1158/1078-0432.Ccr-20-2584 https://doi.org/10.1158/1078-0432.Ccr-20-2584

Krijgsman O , Kemper K , Boshuizen J , et al. , 2021 . Predictive immune-checkpoint blockade classifiers identify tumors responding to inhibition of PD-1 and/or CTLA-4 . Clin Cancer Res , 27 ( 19 ): 5389 - 5400 . https://doi.org/10.1158/1078-0432.Ccr-20-4218 https://doi.org/10.1158/1078-0432.Ccr-20-4218

Kuroki K , Furukawa A , Maenaka K , 2012 . Molecular recognition of paired receptors in the immune system . Front Microbiol , 3 : 429 . https://doi.org/10.3389/fmicb.2012.00429 https://doi.org/10.3389/fmicb.2012.00429

Le DT , Uram JN , Wang H , et al. , 2015 . PD-1 blockade in tumors with mismatch-repair deficiency . N Engl J Med , 372 ( 26 ): 2509 - 2520 . https://doi.org/10.1056/NEJMoa1500596 https://doi.org/10.1056/NEJMoa1500596

Levin SD , Taft DW , Brandt CS , et al. , 2011 . Vstm3 is a member of the CD28 family and an important modulator of T-cell function . Eur J Immunol , 41 ( 4 ): 902 - 915 . https://doi.org/10.1002/eji.201041136 https://doi.org/10.1002/eji.201041136

Li B , Chan HL , Chen PP , 2019 . Immune checkpoint inhibitors: basics and challenges . Curr Med Chem , 26 ( 17 ): 3009 - 3025 . https://doi.org/10.2174/0929867324666170804143706 https://doi.org/10.2174/0929867324666170804143706

Li C , Zhan YD , Ma XZ , et al. , 2020 . B7-H4 facilitates proliferation and metastasis of colorectal carcinoma cell through PI3K/Akt/mTOR signaling pathway . Clin Exp Med , 20 ( 1 ): 79 - 86 . https://doi.org/10.1007/s10238-019-00590-7 https://doi.org/10.1007/s10238-019-00590-7

Li HX , van der Merwe PA , Sivakumar S , 2022 . Biomarkers of response to PD-1 pathway blockade . Br J Cancer , 126 ( 12 ): 1663 - 1675 . https://doi.org/10.1038/s41416-022-01743-4 https://doi.org/10.1038/s41416-022-01743-4

Li HY , Piao L , Liu SC , et al. , 2020 . B7-H4 is a potential prognostic biomarker of prostate cancer . Exp Mol Pathol , 114 : 104406 . https://doi.org/10.1016/j.yexmp.2020.104406 https://doi.org/10.1016/j.yexmp.2020.104406

Li J , Lee Y , Li YJ , et al. , 2018 . Co-inhibitory molecule B7 superfamily member 1 expressed by tumor-infiltrating myeloid cells induces dysfunction of anti-tumor CD8 + T cells . Immunity , 48 ( 4 ): 773 - 786.e5 . https://doi.org/10.1016/j.immuni.2018.03.018 https://doi.org/10.1016/j.immuni.2018.03.018

Li M , Xia PY , Du Y , et al. , 2014 . T-cell immunoglobulin and ITIM domain (TIGIT) receptor/poliovirus receptor (PVR) ligand engagement suppresses interferon-γ production of natural killer cells via β-arrestin 2-mediated negative signaling . J Biol Chem , 289 ( 25 ): 17647 - 17657 . https://doi.org/10.1074/jbc.M114.572420 https://doi.org/10.1074/jbc.M114.572420

Li T , Li XY , Zamani A , et al. , 2020 . c-Rel is a myeloid checkpoint for cancer immunotherapy . Nat Cancer , 1 ( 5 ): 507 - 517 . https://doi.org/10.1038/s43018-020-0061-3 https://doi.org/10.1038/s43018-020-0061-3

Li XM , Xu ZG , Cui GY , et al. , 2020 . BTLA expression in stage I-III non-small-cell lung cancer and its correlation with PD-1/PD-L1 and clinical outcomes . Onco Targets Ther , 13 : 215 - 224 . https://doi.org/10.2147/ott.S232234 https://doi.org/10.2147/ott.S232234

Lines JL , Pantazi E , Mak J , et al. , 2014a . VISTA is an immune checkpoint molecule for human T cells . Cancer Res , 74 ( 7 ): 1924 - 1932 . https://doi.org/10.1158/0008-5472.CAN-13-1504 https://doi.org/10.1158/0008-5472.CAN-13-1504

Lines JL , Sempere LF , Broughton T , et al. , 2014b . VISTA is a novel broad-spectrum negative checkpoint regulator for cancer immunotherapy . Cancer Immunol Res , 2 ( 6 ): 510 - 517 . https://doi.org/10.1158/2326-6066.CIR-14-0072 https://doi.org/10.1158/2326-6066.CIR-14-0072

Linsley PS , Bradshaw J , Greene J , et al. , 1996 . Intracellular trafficking of CTLA-4 and focal localization towards sites of TCR engagement . Immunity , 4 ( 6 ): 535 - 543 . https://doi.org/10.1016/s1074-7613(00)80480-x https://doi.org/10.1016/s1074-7613(00)80480-x

Liu S , Zhang H , Li M , et al. , 2013 . Recruitment of Grb2 and SHIP1 by the ITT-like motif of TIGIT suppresses granule polarization and cytotoxicity of NK cells . Cell Death Differ , 20 ( 3 ): 456 - 464 . https://doi.org/10.1038/cdd.2012.141 https://doi.org/10.1038/cdd.2012.141

Liu YT , Sun ZJ , 2021 . Turning cold tumors into hot tumors by improving T-cell infiltration . Theranostics , 11 ( 11 ): 5365 - 5386 . https://doi.org/10.7150/thno.58390 https://doi.org/10.7150/thno.58390

Loyet KM , Ouyang WJ , Eaton DL , et al. , 2005 . Proteomic profiling of surface proteins on Th1 and Th2 cells . J Proteome Res , 4 ( 2 ): 400 - 409 . https://doi.org/10.1021/pr049810q https://doi.org/10.1021/pr049810q

Luo N , Nixon MJ , Gonzalez-Ericsson PI , et al. , 2018 . DNA methyltransferase inhibition upregulates MHC-I to potentiate cytotoxic T lymphocyte responses in breast cancer . Nat Commun , 9 : 248 . https://doi.org/10.1038/s41467-017-02630-w https://doi.org/10.1038/s41467-017-02630-w

Ma J , Song YQ , Xie Y , et al. , 2022 . Phase I study of the anti-BTLA antibody tifcemalimab as a single agent or in combination with toripalimab in relapsed/refractory lymphomas . Blood , 140 ( S1 ): 3716 - 3717 . https://doi.org/10.1182/blood-2022-157497 https://doi.org/10.1182/blood-2022-157497

Ma R , Li ZL , Chiocca EA , et al. , 2023 . The emerging field of oncolytic virus-based cancer immunotherapy . Trends Cancer , 9 ( 2 ): 122 - 139 . https://doi.org/10.1016/j.trecan.2022.10.003 https://doi.org/10.1016/j.trecan.2022.10.003

Macauley MS , Crocker PR , Paulson JC , 2014 . Siglec-mediated regulation of immune cell function in disease . Nat Rev Immunol , 14 ( 10 ): 653 - 666 . https://doi.org/10.1038/nri3737 https://doi.org/10.1038/nri3737

Mahadevan NR , Knelson EH , Wolff JO , et al. , 2021 . Intrinsic immunogenicity of small cell lung carcinoma revealed by its cellular plasticity . Cancer Discov , 11 ( 8 ): 1952 - 1969 . https://doi.org/10.1158/2159-8290.Cd-20-0913 https://doi.org/10.1158/2159-8290.Cd-20-0913

Marijt KA , Sluijter M , Blijleven L , et al. , 2019 . Metabolic stress in cancer cells induces immune escape through a PI3K-dependent blockade of IFNγ receptor signaling . J Immunother Cancer , 7 ( 1 ): 152 . https://doi.org/10.1186/s40425-019-0627-8 https://doi.org/10.1186/s40425-019-0627-8

Martinez GJ , Pereira RM , Äijö T , et al. , 2015 . The transcription factor NFAT promotes exhaustion of activated CD8 + T cells . Immunity , 42 ( 2 ): 265 - 278 . https://doi.org/10.1016/j.immuni.2015.01.006 https://doi.org/10.1016/j.immuni.2015.01.006

Martins F , Sofiya L , Sykiotis GP , et al. , 2019 . Adverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillance . Nat Rev Clin Oncol , 16 ( 9 ): 563 - 580 . https://doi.org/10.1038/s41571-019-0218-0 https://doi.org/10.1038/s41571-019-0218-0

Mendelsohn CL , Wimmer E , Racaniello VR , 1989 . Cellular receptor for poliovirus: molecular cloning, nucleotide sequence, and expression of a new member of the immunoglobulin superfamily . Cell , 56 ( 5 ): 855 - 865 . https://doi.org/10.1016/0092-8674(89)90690-9 https://doi.org/10.1016/0092-8674(89)90690-9

Merchant YP , Mehta V , Aaqib Shamim M , et al. , 2023 . Cost-benefit analysis of immune checkpoint inhibitors: is the price worth their value? Oral Oncol , 146 : 106560 . https://doi.org/10.1016/j.oraloncology.2023.106560 https://doi.org/10.1016/j.oraloncology.2023.106560

Meric-Bernstam F , Larkin J , Tabernero J , et al. , 2021 . Enhancing anti-tumour efficacy with immunotherapy combinations . Lancet , 397 ( 10278 ): 1010 - 1022 . https://doi.org/10.1016/s0140-6736(20)32598-8 https://doi.org/10.1016/s0140-6736(20)32598-8

Mettu NB , Ulahannan SV , Bendell JC , et al. , 2022 . A phase 1a/b open-label, dose-escalation study of etigilimab alone or in combination with nivolumab in patients with locally advanced or metastatic solid tumors . Clin Cancer Res , 28 ( 5 ): 882 - 892 . https://doi.org/10.1158/1078-0432.Ccr-21-2780 https://doi.org/10.1158/1078-0432.Ccr-21-2780

M'Hidi H , Thibult ML , Chetaille B , et al. , 2009 . High expression of the inhibitory receptor BTLA in T-follicular helper cells and in B-cell small lymphocytic lymphoma/chronic lymphocytic leukemia . Am J Clin Pathol , 132 ( 4 ): 589 - 596 . https://doi.org/10.1309/ajcpphkgyyggl39c https://doi.org/10.1309/ajcpphkgyyggl39c

Modak S , Zanzonico P , Grkovski M , et al. , 2020 . B7H3-directed intraperitoneal radioimmunotherapy with radioiodinated omburtamab for desmoplastic small round cell tumor and other peritoneal tumors: results of a phase I study . J Clin Oncol , 38 ( 36 ): 4283 - 4291 . https://doi.org/10.1200/jco.20.01974 https://doi.org/10.1200/jco.20.01974

Monney L , Sabatos CA , Gaglia JL , et al. , 2002 . Th1-specific cell surface protein Tim-3 regulates macrophage activation and severity of an autoimmune disease . Nature , 415 ( 6871 ): 536 - 541 . https://doi.org/10.1038/415536a https://doi.org/10.1038/415536a

Morad G , Helmink BA , Sharma P , et al. , 2021 . Hallmarks of response, resistance, and toxicity to immune checkpoint blockade . Cell , 184 ( 21 ): 5309 - 5337 . https://doi.org/10.1016/j.cell.2021.09.020 https://doi.org/10.1016/j.cell.2021.09.020

Murtaza A , Laken H , da Silva Correia J , et al. , 2016 . Discovery of TSR-022, a novel, potent anti-human TIM-3 therapeutic antibody . Eur J Cancer , 69 ( S1 ): S102 . https://doi.org/10.1016/S0959-8049(16)32903-3 https://doi.org/10.1016/S0959-8049(16)32903-3

Musielak B , Kocik J , Skalniak L , et al. , 2019 . CA-170—a potent small-molecule PD-L1 inhibitor or not? Molecules , 24 ( 15 ): 2804 . https://doi.org/10.3390/molecules24152804 https://doi.org/10.3390/molecules24152804

Nakamura K , Smyth MJ , 2020 . Myeloid immunosuppression and immune checkpoints in the tumor microenvironment . Cell Mol Immunol , 17 ( 1 ): 1 - 12 . https://doi.org/10.1038/s41423-019-0306-1 https://doi.org/10.1038/s41423-019-0306-1

Nakanishi K , Yoshimoto T , Tsutsui H , et al. , 2001 . Interleukin-18 is a unique cytokine that stimulates both Th1 and Th2 responses depending on its cytokine milieu . Cytokine Growth Factor Rev , 12 ( 1 ): 53 - 72 . https://doi.org/10.1016/s1359-6101(00)00015-0 https://doi.org/10.1016/s1359-6101(00)00015-0

Nakayama M , Akiba H , Takeda K , et al. , 2009 . Tim-3 mediates phagocytosis of apoptotic cells and cross-presentation . Blood , 113 ( 16 ): 3821 - 3830 . https://doi.org/10.1182/blood-2008-10-185884 https://doi.org/10.1182/blood-2008-10-185884

Niu J , Maurice-Dror C , Lee DH , et al. , 2021 . First-in-human phase 1 study of the anti-TIGIT antibody vibostolimab as monotherapy or with pembrolizumab for advanced solid tumors, including non-small-cell lung cancer . Ann Oncol , 33 ( 2 ): 169 - 180 . https://doi.org/10.1016/j.annonc.2021.11.002 https://doi.org/10.1016/j.annonc.2021.11.002

Nurieva RI , Chung Y , Hwang D , et al. , 2008 . Generation of T follicular helper cells is mediated by interleukin-21 but independent of T helper 1, 2, or 17 cell lineages . Immunity , 29 ( 1 ): 138 - 149 . https://doi.org/10.1016/j.immuni.2008.05.009 https://doi.org/10.1016/j.immuni.2008.05.009

Panelli MC , White R , Foster M , et al. , 2004 . Forecasting the cytokine storm following systemic interleukin (IL)-2 administration . J Transl Med , 2 : 17 . https://doi.org/10.1186/1479-5876-2-17 https://doi.org/10.1186/1479-5876-2-17

Pardoll DM , 2012 . Immunology beats cancer: a blueprint for successful translation . Nat Immunol , 13 ( 12 ): 1129 - 1132 . https://doi.org/10.1038/ni.2392 https://doi.org/10.1038/ni.2392

Park SY , Kim IS , 2019 . Harnessing immune checkpoints in myeloid lineage cells for cancer immunotherapy . Cancer Lett , 452 : 51 - 58 . https://doi.org/10.1016/j.canlet.2019.03.018 https://doi.org/10.1016/j.canlet.2019.03.018

Patil NS , Nabet BY , Müller S , et al. , 2022 . Intratumoral plasma cells predict outcomes to PD-L1 blockade in non-small cell lung cancer . Cancer Cell , 40 ( 3 ): 289 - 300.e4 . https://doi.org/10.1016/j.ccell.2022.02.002 https://doi.org/10.1016/j.ccell.2022.02.002

Pauken KE , Dougan M , Rose NR , et al. , 2019 . Adverse events following cancer immunotherapy: obstacles and opportun ities. Trends Immunol , 40 ( 6 ): 511 - 523 . https://doi.org/10.1016/j.it.2019.04.002 https://doi.org/10.1016/j.it.2019.04.002

Peng WY , Chen JQ , Liu CW , et al. , 2016 . Loss of PTEN promotes resistance to T cell-mediated immunotherapy . Cancer Discov , 6 ( 2 ): 202 - 216 . https://doi.org/10.1158/2159-8290.Cd-15-0283 https://doi.org/10.1158/2159-8290.Cd-15-0283

Picarda E , Ohaegbulam KC , Zang XX , 2016 . Molecular pathways: targeting B7-H3 (CD276) for human cancer immunotherapy . Clin Cancer Res , 22 ( 14 ): 3425 - 3431 . https://doi.org/10.1158/1078-0432.CCR-15-2428 https://doi.org/10.1158/1078-0432.CCR-15-2428

Propper DJ , Balkwill FR , 2022 . Harnessing cytokines and chemokines for cancer therapy . Nat Rev Clin Oncol , 19 ( 4 ): 237 - 253 . https://doi.org/10.1038/s41571-021-00588-9 https://doi.org/10.1038/s41571-021-00588-9

Radhakrishnan V , Banavali S , Gupta S , et al. , 2019 . Excellent CBR and prolonged PFS in non-squamous NSCLC with oral CA-170, an inhibitor of VISTA and PD-L1 . Ann Oncol , 30 (S5):v494. https://doi.org/10.1093/annonc/mdz253.035 https://doi.org/10.1093/annonc/mdz253.035

Ready NE , Ott PA , Hellmann MD , et al. , 2020 . Nivolumab monotherapy and nivolumab plus ipilimumab in recurrent small cell lung cancer: results from the CheckMate 032 randomized cohort . J Thorac Oncol , 15 ( 3 ): 426 - 435 . https://doi.org/10.1016/j.jtho.2019.10.004 https://doi.org/10.1016/j.jtho.2019.10.004

Reck M , Rodríguez-Abreu D , Robinson AG , et al. , 2016 . Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer . N Engl J Med , 375 ( 19 ): 1823 - 1833 . https://doi.org/10.1056/NEJMoa1606774 https://doi.org/10.1056/NEJMoa1606774

Reckamp KL , Redman MW , Dragnev KH , et al. , 2022 . Phase II randomized study of ramucirumab and pembrolizumab versus standard of care in advanced non-small-cell lung cancer previously treated with immunotherapy-lung-map S1800A . J Clin Oncol , 40 ( 21 ): 2295 - 2307 . https://doi.org/10.1200/JCO.22.00912 https://doi.org/10.1200/JCO.22.00912

Ribas A , Wolchok JD , 2018 . Cancer immunotherapy using checkpoint blockade . Science , 359 ( 6382 ): 1350 - 1355 . https://doi.org/10.1126/science.aar4060 https://doi.org/10.1126/science.aar4060

Robert C , Long GV , Brady B , et al. , 2015 . Nivolumab in previously untreated melanoma without BRAF mutation . N Engl J Med , 372 ( 4 ): 320 - 330 . https://doi.org/10.1056/NEJMoa1412082 https://doi.org/10.1056/NEJMoa1412082

Robertson MJ , Mier JW , Logan T , et al. , 2006 . Clinical and biological effects of recombinant human interleukin-18 administered by intravenous infusion to patients with advanced cancer . Clin Cancer Res , 12 ( 14 ): 4265 - 4273 . https://doi.org/10.1158/1078-0432.Ccr-06-0121 https://doi.org/10.1158/1078-0432.Ccr-06-0121

Robertson MJ , Kirkwood JM , Logan TF , et al. , 2008 . A dose-escalation study of recombinant human interleukin-18 using two different schedules of administration in patients with cancer . Clin Cancer Res , 14 ( 11 ): 3462 - 3469 . https://doi.org/10.1158/1078-0432.Ccr-07-4740 https://doi.org/10.1158/1078-0432.Ccr-07-4740

Rosenthal R , Cadieux EL , Salgado R , et al. , 2019 . Neoantigen-directed immune escape in lung cancer evolution . Nature , 567 ( 7749 ): 479 - 485 . https://doi.org/10.1038/s41586-019-1032-7 https://doi.org/10.1038/s41586-019-1032-7

Rotte A , 2019 . Combination of CTLA-4 and PD-1 blockers for treatment of cancer . J Exp Clin Cancer Res , 38 : 255 . https://doi.org/10.1186/s13046-019-1259-z https://doi.org/10.1186/s13046-019-1259-z

Rudd CE , Taylor A , Schneider H , 2009 . CD28 and CTLA-4 coreceptor expression and signal transduction . Immunol Rev , 229 ( 1 ): 12 - 26 . https://doi.org/10.1111/j.1600-065X.2009.00770.x https://doi.org/10.1111/j.1600-065X.2009.00770.x

Sade-Feldman M , Jiao YJ , Chen JH , et al. , 2017 . Resistance to checkpoint blockade therapy through inactivation of antigen presentation . Nat Commun , 8 : 1136 . https://doi.org/10.1038/s41467-017-01062-w https://doi.org/10.1038/s41467-017-01062-w

Salmi M , Koskinen K , Henttinen T , et al. , 2004 . Clever-1 mediates lymphocyte transmigration through vascular and lymphatic endothelium . Blood , 104 ( 13 ): 3849 - 3857 . https://doi.org/10.1182/blood-2004-01-0222 https://doi.org/10.1182/blood-2004-01-0222

Sanmamed MF , Chen LP , 2018 . A paradigm shift in cancer immunotherapy: from enhancement to normalization . Cell , 175 ( 2 ): 313 - 326 . https://doi.org/10.1016/j.cell.2018.09.035 https://doi.org/10.1016/j.cell.2018.09.035

Sansom DM , 2000 . CD28, CTLA-4 and their ligands: who does what and to whom? Immunology , 101 ( 2 ): 169 - 177 . https://doi.org/10.1046/j.1365-2567.2000.00121.x https://doi.org/10.1046/j.1365-2567.2000.00121.x

Schöffski P , Tan DSW , Martín M , et al. , 2022 . Phase I/II study of the LAG-3 inhibitor ieramilimab (LAG525) ± anti-PD-1 spartalizumab (PDR001) in patients with advanced malignancies . J Immunother Cancer , 10 ( 2 ): e003776 . https://doi.org/10.1136/jitc-2021-003776 https://doi.org/10.1136/jitc-2021-003776

Sedy JR , Gavrieli M , Potter KG , et al. , 2005 . B and T lymphocyte attenuator regulates T cell activation through interaction with herpesvirus entry mediator . Nat Immunol , 6 ( 1 ): 90 - 98 . https://doi.org/10.1038/ni1144 https://doi.org/10.1038/ni1144

Sharma P , Hu-Lieskovan S , Wargo JA , et al. , 2017 . Primary, adaptive, and acquired resistance to cancer immunotherapy . Cell , 168 ( 4 ): 707 - 723 . https://doi.org/10.1016/j.cell.2017.01.017 https://doi.org/10.1016/j.cell.2017.01.017

Shigeoka M , Urakawa N , Nakamura T , et al. , 2013 . Tumor associated macrophage expressing CD204 is associated with tumor aggressiveness of esophageal squamous cell carcinoma . Cancer Sci , 104 ( 8 ): 1112 - 1119 . https://doi.org/10.1111/cas.12188 https://doi.org/10.1111/cas.12188

Sordo-Bahamonde C , Lorenzo-Herrero S , Gonzalez-Rodriguez AP , et al. , 2021 . BTLA/HVEM axis induces NK cell immunosuppression and poor outcome in chronic lymphocytic leukemia . Cancers , 13 ( 8 ): 1766 . https://doi.org/10.3390/cancers13081766 https://doi.org/10.3390/cancers13081766

Spranger S , Bao RY , Gajewski TF , 2015 . Melanoma-intrinsic β-catenin signalling prevents anti-tumour immunity . Nature , 523 ( 7559 ): 231 - 235 . https://doi.org/10.1038/nature14404 https://doi.org/10.1038/nature14404

Srivastava S , Pelloso D , Feng HL , et al. , 2013 . Effects of interleukin-18 on natural killer cells: costimulation of activation through Fc receptors for immunoglobulin . Cancer Immunol Immunother , 62 ( 6 ): 1073 - 1082 . https://doi.org/10.1007/s00262-013-1403-0 https://doi.org/10.1007/s00262-013-1403-0

Stanietsky N , Simic H , Arapovic J , et al. , 2009 . The interaction of TIGIT with PVR and PVRL2 inhibits human NK cell cytotoxicity . Proc Natl Acad Sci USA , 106 ( 42 ): 17858 - 17863 . https://doi.org/10.1073/pnas.0903474106 https://doi.org/10.1073/pnas.0903474106

Sullivan RJ , Weber JS , 2022 . Immune-related toxicities of checkpoint inhibitors: mechanisms and mitigation strategies . Nat Rev Drug Discov , 21 ( 7 ): 495 - 508 . https://doi.org/10.1038/s41573-021-00259-5 https://doi.org/10.1038/s41573-021-00259-5

Sumimoto H , Imabayashi F , Iwata T , et al. , 2006 . The BRAF‒MAPK signaling pathway is essential for cancer-immune evasion in human melanoma cells . J Exp Med , 203 ( 7 ): 1651 - 1656 . https://doi.org/10.1084/jem.20051848 https://doi.org/10.1084/jem.20051848

Sznol M , Postow MA , Davies MJ , et al. , 2017 . Endocrine-related adverse events associated with immune checkpoint blockade and expert insights on their management . Cancer Treat Rev , 58 : 70 - 76 . https://doi.org/10.1016/j.ctrv.2017.06.002 https://doi.org/10.1016/j.ctrv.2017.06.002

Tan SY , Xu Y , Wang ZH , et al. , 2020 . Tim-3 hampers tumor surveillance of liver-resident and conventional NK cells by disrupting PI3K signaling . Cancer Res , 80 ( 5 ): 1130 - 1142 . https://doi.org/10.1158/0008-5472.Can-19-2332 https://doi.org/10.1158/0008-5472.Can-19-2332

Tawbi HA , Schadendorf D , Lipson EJ , et al. , 2022 . Relatlimab and nivolumab versus nivolumab in untreated advanced melanoma . N Engl J Med , 386 ( 1 ): 24 - 34 . https://doi.org/10.1056/NEJMoa2109970 https://doi.org/10.1056/NEJMoa2109970

Topalian SL , Taube JM , Anders RA , et al. , 2016 . Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy . Nat Rev Cancer , 16 ( 5 ): 275 - 287 . https://doi.org/10.1038/nrc.2016.36 https://doi.org/10.1038/nrc.2016.36

Torino F , Corsello SM , Salvatori R , 2016 . Endocrinological side-effects of immune checkpoint inhibitors . Curr Opin Oncol , 28 ( 4 ): 278 - 287 . https://doi.org/10.1097/cco.0000000000000293 https://doi.org/10.1097/cco.0000000000000293

Triebel F , Jitsukawa S , Baixeras E , et al. , 1990 . LAG-3, a novel lymphocyte activation gene closely related to CD4 . J Exp Med , 171 ( 5 ): 1393 - 1405 . https://doi.org/10.1084/jem.171.5.1393 https://doi.org/10.1084/jem.171.5.1393

Upadhaya S , Neftelinov ST , Hodge J , et al. , 2022 . Challenges and opportunities in the PD1/PDL1 inhibitor clinical trial landscape . Nat Rev Drug Discov , 21 ( 7 ): 482 - 483 . https://doi.org/10.1038/d41573-022-00030-4 https://doi.org/10.1038/d41573-022-00030-4

Virgin HW , Wherry EJ , Ahmed R , 2009 . Redefining chronic viral infection . Cell , 138 ( 1 ): 30 - 50 . https://doi.org/10.1016/j.cell.2009.06.036 https://doi.org/10.1016/j.cell.2009.06.036

Voron T , Colussi O , Marcheteau E , et al. , 2015 . VEGF-A modulates expression of inhibitory checkpoints on CD8 + T cells in tumors . J Exp Med , 212 ( 2 ): 139 - 148 . https://doi.org/10.1084/jem.20140559 https://doi.org/10.1084/jem.20140559

Wainberg ZA , Sachdev JC , Bauer T , et al. , 2019 . FPA150 (B7-H4 antibody) phase I update in advanced solid tumours: monotherapy and in combination with pembrolizumab . Ann Oncol , 30 (S5):V489. https://doi.org/10.1093/annonc/mdz253.024 https://doi.org/10.1093/annonc/mdz253.024

Wang JH , Wu GP , Manick B , et al. , 2019 . VSIG-3 as a ligand of VISTA inhibits human T-cell function . Immunology , 156 ( 1 ): 74 - 85 . https://doi.org/10.1111/imm.13001 https://doi.org/10.1111/imm.13001

Wang L , Rubinstein R , Lines JL , et al. , 2011 . VISTA, a novel mouse Ig superfamily ligand that negatively regulates T cell responses . J Exp Med , 208 ( 3 ): 577 - 592 . https://doi.org/10.1084/jem.20100619 https://doi.org/10.1084/jem.20100619

Wang SX , Li YS , Liu ZQ , et al. , 2023 . Efficacy and safety of first-line immune checkpoint inhibitors combined with chemotherapy for extensive-stage small cell lung cancer: a network meta-analysis . Lung Cancer , 178 : 47 - 56 . https://doi.org/10.1016/j.lungcan.2023.02.003 https://doi.org/10.1016/j.lungcan.2023.02.003

Wang XX , Barrera C , Bera K , et al. , 2022 . Spatial interplay patterns of cancer nuclei and tumor-infiltrating lymphocytes (TILs) predict clinical benefit for immune checkpoint inhibitors . Sci Adv , 8 ( 22 ): eabn3966 . https://doi.org/10.1126/sciadv.abn3966 https://doi.org/10.1126/sciadv.abn3966

Watanabe N , Gavrieli M , Sedy JR , et al. , 2003 . BTLA is a lymphocyte inhibitory receptor with similarities to CTLA-4 and PD-1 . Nat Immunol , 4 ( 7 ): 670 - 679 . https://doi.org/10.1038/ni944 https://doi.org/10.1038/ni944

Weber JS , Kähler KC , Hauschild A , 2012 . Management of immune-related adverse events and kinetics of response with ipilimumab . J Clin Oncol , 30 ( 21 ): 2691 - 2697 . https://doi.org/10.1200/jco.2012.41.6750 https://doi.org/10.1200/jco.2012.41.6750

Wolchok JD , Neyns B , Linette G , et al. , 2010 . Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study . Lancet Oncol , 11 ( 2 ): 155 - 164 . https://doi.org/10.1016/s1470-2045(09)70334-1 https://doi.org/10.1016/s1470-2045(09)70334-1

Wolchok JD , Chiarion-Sileni V , Gonzalez R , et al. , 2022 . Long-term outcomes with nivolumab plus ipilimumab or nivolumab alone versus ipilimumab in patients with advanced melanoma . J Clin Oncol , 40 ( 2 ): 127 - 137 . https://doi.org/10.1200/jco.21.02229 https://doi.org/10.1200/jco.21.02229

Wolf Y , Anderson AC , Kuchroo VK , 2020 . TIM3 comes of age as an inhibitory receptor . Nat Rev Immunol , 20 ( 3 ): 173 - 185 . https://doi.org/10.1038/s41577-019-0224-6 https://doi.org/10.1038/s41577-019-0224-6

Workman CJ , Vignali DAA , 2005 . Negative regulation of T cell homeostasis by lymphocyte activation gene-3 (CD223) . J Immunol , 174 ( 2 ): 688 - 695 . https://doi.org/10.4049/jimmunol.174.2.688 https://doi.org/10.4049/jimmunol.174.2.688

Workman CJ , Rice DS , Dugger KJ , et al. , 2002 . Phenotypic analysis of the murine CD4-related glycoprotein, CD223 (LAG-3) . Eur J Immunol , 32 ( 8 ): 2255 - 2263 . https://doi.org/10.1002/1521-4141(200208)32:8<2255::Aid-immu2255>3.0.Co;2-a https://doi.org/10.1002/1521-4141(200208)32:8<2255::Aid-immu2255>3.0.Co;2-a

Workman CJ , Wang Y , El Kasmi KC , et al. , 2009 . LAG-3 regulates plasmacytoid dendritic cell homeostasis . J Immunol , 182 ( 4 ): 1885 - 1891 . https://doi.org/10.4049/jimmunol.0800185 https://doi.org/10.4049/jimmunol.0800185

Wu CY , Cao X , Zhang XJ , 2021 . VISTA inhibitors in cancer immunotherapy: a short perspective on recent progresses . RSC Med Chem , 12 ( 10 ): 1672 - 1679 . https://doi.org/10.1039/d1md00185j https://doi.org/10.1039/d1md00185j

Xiao YL , Chen J , Zhou H , et al. , 2022 . Combining p53 mRNA nanotherapy with immune checkpoint blockade reprograms the immune microenvironment for effective cancer therapy . Nat Commun , 13 : 758 . https://doi.org/10.1038/s41467-022-28279-8 https://doi.org/10.1038/s41467-022-28279-8

Xu C , Chen YP , Du XJ , et al. , 2018 . Comparative safety of immune checkpoint inhibitors in cancer: systematic review and network meta-analysis . BMJ , 363 : k4226 . https://doi.org/10.1136/bmj.k4226 https://doi.org/10.1136/bmj.k4226

Xu L , Yan X , Ding WY , 2022 . Meta-analysis of efficacy from CTLA-4 and PD-1/PD-L1 inhibitors in cancer patients . Front Oncol , 12 : 876098 . https://doi.org/10.3389/fonc.2022.876098 https://doi.org/10.3389/fonc.2022.876098

Yao S , Wang SD , Zhu YW , et al. , 2009 . PD-1 on dendritic cells impedes innate immunity against bacterial infection . Blood , 113 ( 23 ): 5811 - 5818 . https://doi.org/10.1182/blood-2009-02-203141 https://doi.org/10.1182/blood-2009-02-203141

Yarchoan M , Hopkins A , Jaffee EM , 2017 . Tumor mutational burden and response rate to PD-1 inhibition . N Engl J Med , 377 ( 25 ): 2500 - 2501 . https://doi.org/10.1056/NEJMc1713444 https://doi.org/10.1056/NEJMc1713444

Yasuda K , Nakanishi K , Tsutsui H , 2019 . Interleukin-18 in health and disease . Int J Mol Sci , 20 ( 3 ): 649 . https://doi.org/10.3390/ijms20030649 https://doi.org/10.3390/ijms20030649

Ye Q , Shen Y , Wang X , et al. , 2010 . Hypermethylation of HLA class I gene is associated with HLA class I down-regulation in human gastric cancer . Tissue Antigens , 75 ( 1 ): 30 - 39 . https://doi.org/10.1111/j.1399-0039.2009.01390.x https://doi.org/10.1111/j.1399-0039.2009.01390.x

Yin YZ , Shi LL , Yang J , et al. , 2022 . B7 family member H4 induces epithelial-mesenchymal transition and promotes the proliferation, migration and invasion of colorectal cancer cells . Bioengineered , 13 ( 1 ): 107 - 118 . https://doi.org/10.1080/21655979.2021.2009411 https://doi.org/10.1080/21655979.2021.2009411

Yu X , Harden K , Gonzalez LC , et al. , 2009 . The surface protein TIGIT suppresses T cell activation by promoting the generation of mature immunoregulatory dendritic cells . Nat Immunol , 10 ( 1 ): 48 - 57 . https://doi.org/10.1038/ni.1674 https://doi.org/10.1038/ni.1674

Zarour HM , 2016 . Reversing T-cell dysfunction and exhaustion in cancer . Clin Cancer Res , 22 ( 8 ): 1856 - 1864 . https://doi.org/10.1158/1078-0432.Ccr-15-1849 https://doi.org/10.1158/1078-0432.Ccr-15-1849

Zhang RR , Wang LM , Shen JJ , 2020 . Overexpression of miR-32 inhibits the proliferation and metastasis of ovarian cancer cells by targeting BTLA . Eur Rev Med Pharmacol Sci , 24 ( 9 ): 4671 - 4678 . https://doi.org/10.26355/eurrev_202005_21154 https://doi.org/10.26355/eurrev_202005_21154

Zhou T , Damsky W , Weizman OE , et al. , 2020 . IL-18BP is a secreted immune checkpoint and barrier to IL-18 immunotherapy . Nature , 583 ( 7817 ): 609 - 614 . https://doi.org/10.1038/s41586-020-2422-6 https://doi.org/10.1038/s41586-020-2422-6

Zhu C , Anderson AC , Schubart A , et al. , 2005 . The Tim-3 ligand galectin-9 negatively regulates T helper type 1 immunity . Nat Immunol , 6 ( 12 ): 1245 - 1252 . https://doi.org/10.1038/ni1271 https://doi.org/10.1038/ni1271

Zingg D , Arenas-Ramirez N , Sahin D , et al. , 2017 . The histone methyltransferase Ezh2 controls mechanisms of adaptive resistance to tumor immunotherapy . Cell Rep , 20 ( 4 ): 854 - 867 . https://doi.org/10.1016/j.celrep.2017.07.007 https://doi.org/10.1016/j.celrep.2017.07.007

浏览量

Downloads

CSCD

工具集

关联资源

暂无数据